Swiss Re Slips To Loss In Q1, Net Premiums Rise; Expects To Meet FY22 Targets

Swiss reinsurer Swiss Re AG (SSREY.PK) reported Thursday that its first-quarter net loss was $248 million, compared to prior year's net income of $333 million.

The loss was impacted by the war in Ukraine, heightened financial market volatility and the ongoing COVID-19 pandemic.

The company said it absorbed higher-than-expected large natural catastrophe claims of $524 million across its property and casualty businesses as well as COVID-19 claims of $515 million. In addition, Swiss Re booked $283 million in reserves related to the war in Ukraine.

Swiss Re's net premiums earned and fee income, however, increased 4 percent to $10.62 billion from last year's $10.21 billion.

Looking ahead, Swiss Re's Group Chief Executive Officer Christian Mumenthaler said, "While the first quarter of 2022 presented significant headwinds for the re/insurance industry and Swiss Re, we are confident in the Group's ability to navigate the challenges. Thanks to the actions we have taken over the past years, our businesses have all the necessary levers in place to drive profitability and deliver against our financial targets for 2022."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT